Prospective, Non Interventional Study to Evaluate the Safety Profile of First- Line Rituximab Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 28 Dec 2017 Status changed from active, no longer recruiting to completed.
- 03 Oct 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 03 Oct 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.